Healthcare entity
JPMorgan Chase is most often covered alongside Bank of America, which appears in 1 of these 2 stories. The 104-day window averages about 0.1 stories each week. Each story carries 3.5 original sources on average, compared with 4.4 for the broader beat in this window.
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
JPMorgan Chase is most often covered alongside Bank of America, which appears in 1 of these 2 stories. The 104-day window averages about 0.1 stories each week. Each story carries 3.5 original sources on average, compared with 4.4 for the broader beat in this window. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Their average consequence score of 6.5 runs above the beat's 6.3 for that window. JPMorgan Chase appears in 2 tracked Healthcare stories published from March 23, 2026 through July 4, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 158 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JPMorgan Chase. Shared-story counts are live from our verified record — not editorial picks.
JPM Q1 Earnings Report
JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny.
FDA Orforglipron Decision
Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss.
Intuitive Surgical's decision to extend force-feedback tool usage from 6 to 15 uses could accelerate robotic surgery adoption in hospitals, easing supply chain woes and lowering per-procedure costs without sacrificing revenue.
Source: The Motley Fool · James Halley (us)
Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
Source: Adria Cimino (us) · fool.com
JPMorgan Chase is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
